Revolutionary mRNA Drug Shows Promise Against Melanoma Recurrence

A groundbreaking clinical trial has demonstrated that a new mRNA drug, intismeran autogene, holds the potential to significantly reduce the recurrence of melanoma, one of the most lethal forms of skin cancer. Conducted on over 1,100 patients, the trial revealed that when combined with the immunotherapy drug pembrolizumab, intismeran autogene effectively prevented the cancer from returning and spreading to other organs.

The innovative drug leverages the messenger RNA technology that garnered attention during the development of COVID-19 vaccines by Moderna and Pfizer. This marks a significant milestone as it is the first mRNA treatment to yield positive results in a Phase 3 trial for cancer.

Professor Georgina Long, the principal investigator and medical director at the Melanoma Institute Australia, hailed the findings as a "landmark moment for adjuvant melanoma treatment," indicating the possibility of a new therapeutic approach that could keep patients cancer-free for extended periods. Both Merck and Moderna plan to present their findings at an international conference and seek regulatory approval.

The trial, which lasted about a year, involved randomizing participants after their tumors were surgically removed, with two-thirds receiving the combination treatment. This promising development comes as melanoma diagnoses continue to rise, with over 330,000 new cases reported globally in 2022.

Source: www.abc.net.au